Filtered By:
Specialty: Research
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 1545 results found since Jan 2013.
MiR-767-3p promotes the progression of hepatocellular carcinoma via targeting CASP-3/-9
CONCLUSION: MiR-767-3p promoted proliferation and prevented apoptosis in human hepatocellular carcinoma (HCC) through inhibiting the caspase-3/caspase-9 pathway.PMID:37193190 | PMC:PMC10182511
Source: American Journal of Translational Research - May 16, 2023 Category: Research Authors: Maolin Wu Jing Deng Dejiao Yao Shijie Li Source Type: research
SPOCK2 gene expression is downregulated in pancreatic ductal adenocarcinoma cells and correlates with prognosis of patients with pancreatic cancer
CONCLUSION: The expression of SPOCK2 is downregulated in PDAC as a result of hypermethylation of its corresponding gene. SPOCK2 expression as well as the demethylation of its gene could be a potential marker for PDAC.PMID:37188984 | DOI:10.1007/s00432-023-04845-5
Source: Clin Med Res - May 15, 2023 Category: Research Authors: Ughur Aghamaliyev Kaifeng Su Maximilian Weniger Dominik Koch Jan G D'Haese Jens Werner Alexandr V Bazhin Source Type: research
Transfection efficacy and drug release depends upon the PEG derivative in cationic lipoplexes: Evaluation in 3D in vitro model and in vivo
J Biomed Mater Res B Appl Biomater. 2023 May 3. doi: 10.1002/jbm.b.35259. Online ahead of print.ABSTRACTThe goal of the study was to estimate transfection efficacy and drug release in function of the PEG derivative in cationic liposomes and lipoplexes in both 2D and 3D in vitro models as well as in a mouse model (in vivo). For this purpose, cationic PEGylated nanocarriers based on OrnOrnGlu(C16 H33 )2 lipopeptides were fabricated and characterized. The nanocarriers were loaded with DNA plasmid pGL3 or with siRNA targeting 5'-UTR region of Hepatitis C virus, and their transfection efficacies were studied by luciferase test ...
Source: Biomed Res - May 3, 2023 Category: Research Authors: Gileva A M Koloskova O O Nosova A S Vishniakova L I Simonova V A Kurbanova L A Egorenkov E A Smirnov V V Budanova U A Sebyakin Yu L Suzina N E Khaitov M R Markvicheva E Source Type: research
ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression
Aberrant N6-methyladenosine (m6A) modification of mRNAs contributes significantly to the epigenetic tumorigenesis, however, its precise role and the key targets in osteosarcoma (OS) are not defined. Here we reported that selective METTL3 (methyltransferase like 3) elevation and the consequential increase of m6A modification causally affect OS progression. The fast-growing OS cells displayed preferential upregulation of METTL3 and increased m6A modification. Conversely, m6A inhibition by 3-deazaadenosine, siRNA-mediated METTL3 knockdown or a METTL3-selective inhibitor by STM2457 effectively inhibits OS cell growth and induc...
Source: Translational Research - April 28, 2023 Category: Research Authors: Xueying An, Wenshu Wu, Lin Yang, Jian Dong, Bin Liu, Junxia Guo, Jianmei Chen, Baosheng Guo, Wangsen Cao, Qing Jiang Source Type: research
Resveratrol-induced SIRT1 activation inhibits glycolysis-fueled angiogenesis under rheumatoid arthritis conditions independent of HIF-1 α
ConclusionGlycolysis provides additional energy to sustain Rho/ROCK activation in RA subjects, which promotes VEGF-driven angiogenesis and can be inhibited by SIRT1 activation.
Source: Inflammation Research - April 4, 2023 Category: Research Source Type: research
Inhibition of importin-7 attenuates ventilator-induced lung injury by targeting nuclear translocation of p38
ConclusionsOur findings uncover a key role for Imp7 in the process of p38 nuclear import after CS stimulation and highlight the potential of preventing p38 nuclear translocation in treatment of VILI.
Source: Inflammation Research - April 1, 2023 Category: Research Source Type: research
ETS-1/c-Met drives resistance to sorafenib in hepatocellular carcinoma
CONCLUSION: c-Met overexpression and activation is an essential mechanism of sorafenib resistance in HCC. Combination therapy of sorafenib plus c-Met inhibitor overcame the resistance of sorafenib-targeted therapy for HCC.PMID:36915773 | PMC:PMC10006745
Source: American Journal of Translational Research - March 14, 2023 Category: Research Authors: Yongfang Ma Xueke Liu Xiaolong Tang Source Type: research
